Micropharma seeks patent protection for probiotic technologies

Micropharma president and chief executive officer Ryan Jones said, "By patenting our products like Cardioviva, it helps us guarantee to consumers that they will get a rigorously tested, proven probiotic product."

Probiotics are being studied to conclude if they may have an important role in maintaining and improving health and wellness through the gut.

And emerging science is evaluating whether supplementing the microbiome (gut bacteria) with probiotics can play a role in health and certain chronic diseases such as heart disease, according to the company.

Micropharma business development director Dr. Chris Wahl said, "We have several new dietary products in development that will have a tremendous positive impact on health when used as part of a healthy diet and lifestyle."